We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...